The regulator’s Office of Prescription Drug Promotion (OPDP) has already sent out two letters alleging “false or misleading” ...

Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

Hologic has drafted professional basketball player Erica Wheeler to raise awareness of cervical cancer screening, putting the ...

This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care ...

The move comes in response to increasing delivery demands for GLP-1s, plus broader conversations about pharmaceutical ...

In fact, the price of such vouchers has been climbing steadily in recent months, according to public disclosures surrounding ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...